Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
N-MYC–eIF4G1 Signaling in inv(16) AML
2026-09-09
The reference study identifies N-MYC as a previously underappreciated survival regulator in inv(16) acute myeloid leukemia and establishes eIF4G1 as a key downstream effector. By integrating transcriptomic, regulatory, genetic, primary-cell, and xenograft evidence, the work connects CBFβ-SMMHC-associated leukemogenesis with a targetable N-MYC/eIF4G1 dependency.
-
Apicidin: An HDAC Probe for Context-Rich Assays
2026-09-08
Apicidin is a histone deacetylase inhibitor whose effects extend from cancer-cell phenotypes to meiotic and reproductive toxicology. This article explains how to interpret HDAC engagement, acetylation changes, and cell-state outcomes without confusing a useful research probe with a single-pathway explanation.
-
Levofloxacin Workflows for Resistance and Cell Assays
2026-09-08
Levofloxacin can connect bacterial DNA replication studies with quantitative osteoblast and cartilage-metabolism assays. This practical guide converts resistance-surveillance findings into controlled workflows, assay checkpoints, and troubleshooting decisions without treating research observations as clinical dosing guidance.
-
VX-745: Practical p38α MAPK Inhibition Workflows
2026-09-07
VX-745 combines strong p38α preference with practical workflows for cytokine profiling, multiple myeloma research, aging-related fibroblast studies, and inflammatory disease modeling. This guide connects concentration planning, phospho-signaling assays, cytokine endpoints, and troubleshooting without treating kinase inhibition as a one-readout experiment.
-
Stable-Isotope UHPLC–MS/MS for 1-Methyl Ado
2026-09-07
The 2024 Analytical Chemistry study presents a stable isotope-diluted UHPLC–ESI–MS/MS method for simultaneously quantifying 12 purine ribonucleosides, including 10 methylated species. Ammonium bicarbonate-enhanced ionization, solid-phase extraction, and chromatographic isomer separation improved sensitivity and enabled intracellular measurement of modified nucleosides relevant to RNA modification research and biomarker discovery.
-
Hexose Diphosphate: Metabolic Assay Workflows
2026-09-05
Build water-based hexose diphosphate workflows for glycolytic regulation, ischemia models, and carefully controlled inflammation assays. The guide also separates this hexose phosphate from phosphoenolpyruvate, helping researchers translate aging-inflammation findings without misassigning mechanism.
-
Luminescent ATP Cell Viability Assay Kit I for GBM
2026-09-04
The Luminescent ATP Cell Viability Assay Kit I enables rapid, sensitive cell viability measurement across low-to-high cell densities, making it useful for glioblastoma proliferation, drug-response, and cytotoxicity workflows. Its luciferase luminescence detection provides a practical endpoint for translating cytostatic findings into quantitative assay data while preserving the need for orthogonal mechanistic tests.
-
GLI2–PRDX1 Ferroptosis Resistance in Bladder Cancer
2026-09-04
A 2026 Apoptosis study identifies a GLI2–PRDX1 transcriptional axis that suppresses ferroptosis and promotes bladder cancer progression. Its combination of public-data analysis, RNA sequencing, ChIP, loss-of-function, and rescue experiments supports GLI2 inhibition as a strategy for increasing sensitivity to PRDX1-targeting compounds and cisplatin.
-
URB597 Workflows for Pain and FAAH Research
2026-09-03
URB597, also called KDS-4103, offers a selective way to raise anandamide by blocking FAAH rather than reproducing cannabidiol’s broader pharmacology. This guide translates recent inflammatory-pain findings into practical workflows for target engagement, neuroinflammation studies, behavioral phenotyping, and assay troubleshooting.
-
GPR30 in Spinal CCK+ Neurons and Neuropathic Pain
2026-09-03
This reference study identifies GPR30 in spinal cholecystokinin-positive neurons as a cell-type-specific regulator of nerve-injury-induced pain. By combining molecular mapping, synaptic analysis, pathway manipulation, and chemogenetics, it connects spinal GPR30 signaling with AMPA-mediated sensitization and a primary somatosensory cortex-to-dorsal horn circuit.
-
Trypsin BA5744 for Reliable Cell Assays
2026-09-02
Learn how Trypsin (SKU BA5744) can reduce workflow variability in cell viability, proliferation, differentiation, wound healing, and proteolysis studies. This scenario-based guide separates product-supported specifications from assay recommendations and highlights practical controls for reproducible interpretation.
-
GW4064 for FXR Activation in Metabolic Research
2026-09-02
GW4064 is a selective, non-steroidal FXR agonist for connecting receptor activation with lipid metabolism, TLR4 signaling, ferroptosis, and fibrotic phenotypes. This workflow-focused guide shows how to prepare, dose, validate, and troubleshoot GW4064 in LX-2 and broader metabolic research models.
-
Estradiol, GPR30, and Immune Recovery After Shock
2026-09-01
The reference study shows that estradiol restores splenic CD4+ T-lymphocyte proliferation and cytokine production after hemorrhagic shock by limiting endoplasmic reticulum stress through ERα and GPR30, rather than ERβ. Its pharmacological combination of receptor-selective ligands, antagonists, and an ER-stress inducer provides a useful framework for separating classical and rapid estrogen signaling in immune-trauma research.
-
G-1: Selective GPR30 Agonist Workflows
2026-09-01
G-1 enables rapid, receptor-focused experiments spanning calcium signaling, immune dysfunction, cancer-cell migration, and cardiovascular remodeling. This workflow-led guide shows how to separate GPR30 biology from classical estrogen-receptor effects while improving dosing, controls, and assay reproducibility.
-
EdU Imaging Kits (Cy5) for Cardiac Ablation Studies
2026-08-31
EdU Imaging Kits (Cy5) add a direct DNA-synthesis endpoint to cardiomyocyte injury models, helping distinguish reduced metabolic activity from cell-cycle arrest or cell loss after pulsed electric fields. The morphology-preserving click-chemistry workflow supports both spatial fluorescence imaging and quantitative flow cytometry.